ArticleJournal of ovarian research2025
Atractylenolide III mitigates polycystic ovary syndrome by activating FDX1-mediated proliferation of ovarian granulocyte cells via PI3K/AKT/mTOR.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evidence for FOXL2 Association with the Tsc1 Regulatory Region in Mice.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPolycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder among women of reproductive age worldwide. This study aimed to investigate the therapeutic potential and molecular mechanisms of Atractylenolide III (ATL-III), a bioactive compound derived from Atractylodes macrocephala Koidz., in PCOS.
methodsFollicular fluid and granulosa cells (GCs) were collected from women with PCOS. A PCOS mice model was established using dehydroepiandrosterone (DHEA). The body weight, estrous cycle, glucose tolerance, insulin tolerance, and ovarian morphology were measured to assess ovarian function. The knockdown and overexpression of ferredoxin 1 (FDX1) were conducted in human granulosa-like tumor cells (KGN). Viability and proliferation of GCs were evaluated by CCK-8 and EdU staining. RT-qPCR, Western blotting, and immunohistochemical staining were performed to detect molecule expressions in the PCOS patients, PCOS mice, and KGN cells.
resultsFDX1 expression was significantly decreased in both follicular fluid and GCs of PCOS patients. In PCOS mice, ATL-III was first found that improved the estrous cycle, disordered folliculogenesis, glucose tolerance, insulin resistance, and ovarian morphology, and upregulated ovarian FDX1, and proliferating cell nuclear antigen (PCNA) expression. DHEA-induced KGN cells demonstrated FDX1 suppression associated with proliferation inhibition, whereas FDX1 overexpression rescued proliferative capacity. ATL-III restored KGN cell viability and proliferation through FDX1 upregulation. Mechanistically, ATL-III activated PI3K/AKT/mTOR signaling by regulating FDX1 in both PCOS mice and KGN cells.
conclusionOur findings establish ATL-III as a novel regulator of FDX1 that alleviates PCOS via PI3K/AKT/mTOR-mediated GCs proliferation enhancement, positioning it as a promising therapeutic agent for PCOS treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.